Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule SHIP modulators - Neurogene Inc

Drug Profile

Research programme: small molecule SHIP modulators - Neurogene Inc

Alternative Names: AQX-016A; AQX-100; AQX-100 series; AQX-1000 series; AQX-200 series; AQX-252; AQX-273; AQX-278; AQX-300 series; AQX-356; AQX-MN100; AQX-MN106; AQX-MN278; AQX-SHIP inhibitors; AXQ C5; SHIP1 inhibitors

Latest Information Update: 26 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aquinox Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Inositol-1,4,5-trisphosphate 5 phosphatase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haematological disorders; Haematological malignancies; Immunological disorders; Inflammation
  • Discontinued Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 19 Dec 2023 Neurogene Inc has merged with Neoleukin Therapeutics to form Neurogene Inc
  • 09 Aug 2019 Aquinox Pharmaceuticals merged with Neoleukin therapeutics to form Neoleukin Therapeutics
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies in Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top